• Beam Therapeutics presented additional Phase 1/2 topline clinical data at the ATS 2026 International Conference on BEAM-302, its one-time base-editing therapy for alpha-1 antitrypsin deficiency.
• The update reinforced early signs that a single dose can correct the underlying genetic cause of disease, with sustained restoration of protein function that could address both lung and liver manifestations.
• Beam plans to seek accelerated approval, with a pivotal expansion of the ongoing open-label trial expected to add about 50 patients and start in the second half of 2026.
• Detailed, updated BEAM-302 data are slated for presentation at another medical congress later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181600PRIMZONEFULLFEED9722413) on May 18, 2026, and is solely responsible for the information contained therein.